A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme
Sponsor: Clinical Research Center for Solid Tumor, Korea
Listed as NCT00921167, this PHASE2 trial focuses on Astrocytoma and Glioblastoma and remains completed. Sponsored by Clinical Research Center for Solid Tumor, Korea, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Research Center for Solid Tumor, Korea
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .